NASDAQ:MDVN (MDVN) (MDVN) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free MDVN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$81.44▼$81.4450-Day Range N/A52-Week Range$26.41▼$81.48VolumeN/AAverage Volume3.55 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (MDVN) alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About (MDVN) Stock (NASDAQ:MDVN)Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. MDVN Stock News HeadlinesMarch 27, 2024 | nasdaq.comNotable ETF Outflow Detected - HYLBJanuary 28, 2024 | msn.comNearly a thousand take chilly plunge off Oak Street Beach for annual fundraiserApril 26, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… January 8, 2024 | msn.comPackers beat Bears 17-9 to clinch playoff spot, head to DallasDecember 30, 2023 | msn.comGoogle agrees to settle $5-B lawsuit over ‘incognito’ modeDecember 29, 2023 | msn.comKanye West and Wife Bianca Censori Will Have a 'Fiery' Start to 2024, Psychic PredictsSeptember 2, 2023 | thestreet.comMedivation Alzheimer's Drug Fails Pivotal StudyJune 26, 2023 | thestreet.comMedivation (MDVN) Stock Falling After Earnings Estimates CutApril 26, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… June 26, 2023 | thestreet.comMedivation (MDVN) Stock Falling After Earnings Estimates CutJune 13, 2023 | morningstar.comCore Medalist ETFsMay 31, 2023 | bbc.co.ukThe Connor Phillips ShowApril 21, 2023 | thestreet.comIncyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation DealApril 21, 2023 | thestreet.comMedivation Stock Hits New 52-Week High (MDVN)April 1, 2023 | msn.comMavs Lose to Heat, Play-In Hopes Continue to Take Major HitsMarch 8, 2023 | msn.comMillie Bobby Brown is 'ready to leave Stranger ThingsJanuary 26, 2023 | msn.comLake Nacogdoches notches its first 2023 Legacy ShareLunkerJanuary 15, 2023 | msn.comEx-Huddersfield Town boss Danny Cowley pens emotional goodbye message to Portsmouth supportersDecember 29, 2022 | msn.comGoody’s Name Creates Another Addams Family Wednesday MysteryDecember 25, 2022 | thestreet.comMedivation (MDVN) Stock Surges, Will Explore SaleOctober 18, 2022 | finance.yahoo.comJupiter Wellness’s Potential New OTC Drug Could Put Some More Joy Back Into Breast Cancer Survivors’ Lives - Yahoo FinanceOctober 10, 2022 | msn.comNBC played the 'That’s So Raven' theme and people are freaking out about it: Best memes & tweetsOctober 7, 2022 | marketscreener.comPortage Biotech : NOTICE OF ANNUAL GENERAL MEETING - Form 6-K - Marketscreener.comAugust 5, 2022 | msn.comThe Impressions star Sam Gooden dies aged 87July 16, 2022 | thestreet.comCramer's Top Stock Picks: BMY NDLS NFLX MDVN SGEN BMRNMay 31, 2022 | thestreet.comThe 5 Dumbest Things on Wall Street This Week: Aug. 3March 24, 2022 | benzinga.comOption Alert: MDVN 4,950 Jul $65 Call @Bid @$0.30 - Benzinga - BenzingaSee More Headlines Receive MDVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2016Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:MDVN CUSIP58501N10 CIK1011835 Webwww.medivation.com Phone+1-415-5433470FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report MDVN Stock Analysis - Frequently Asked Questions How were (MDVN)'s earnings last quarter? (MDVN) (NASDAQ:MDVN) announced its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to the consensus estimate of $214.52 million. The business's revenue was up 17.4% compared to the same quarter last year. During the same period last year, the company earned $0.58 earnings per share. What other stocks do shareholders of (MDVN) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and This page (NASDAQ:MDVN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (MDVN) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
